1 trial changed in the last 30 days: 0 stopped, 1 with a notable change, 0 with minor changes only.
Primary endpoint(s) modified
Also in this update: Primary completion pushed from Apr 2028 to Jun 2028; Enrollment increased: 14 → 18 participants
Rocket Pharmaceuticals Inc.Phase 2 NCT06092034 Registry history of NCT06092034 on ClinicalTrials.gov (opens the registry)
Updated
| Phase 1 | 2 | |
| Phase 2 | 2 |
| NCT ID | Title | Condition | Status | Updated |
|---|---|---|---|---|
| Phase 2 | ||||
| NCT06092034 | A Gene Therapy Study of RP-A501 in Male Patients With Danon Disease | Danon Disease | Recruiting | 2026-10-06 |
| NCT04248439 | Gene Therapy for Fanconi Anemia, Complementation Group A | Fanconi Anemia Complementation Group A | Active, Not Recruiting | 2025-12-22 |
| Phase 1 | ||||
| NCT07137338 | A Phase 1 AAV Gene Therapy Trial Evaluating Safety and Preliminary Efficacy of RP-A701 in… | Dilated Cardiomyopathy (DCM) | Recruiting | 2026-10-01 |
| NCT05885412 | A Phase 1, Dose Escalation Trial of RP-A601 in Subjects With PKP2 Variant-Mediated… | PKP2 Arrhythmogenic Cardiomyopathy (PKP2-ACM) | Recruiting | 2026-04-16 |
| Not specified | ||||
| NCT06644742 | PKP2-ACM Natural History Study | Cardiomyopathies | Recruiting | 2026-10-14 |
| NCT06214507 | Danon Disease Natural History Study | Danon Disease | Recruiting | 2026-07-28 |
| NCT07527975 | Long-Term Follow-up: Phase I/II Clinical Study to Evaluate the Safety and Efficacy of the… | Fanconi Anemia | Enrolling by Invitation | 2026-04-14 |
| NCT04437771 | Long-Term Follow-up of Subjects With Fanconi Anaemia Subtype A Treated With ex Vivo Gene… | Fanconi Anemia Complementation Group A | Active, Not Recruiting | 2026-04-13 |
| NCT07486752 | BAG3-DCM Natural History Study | Dilated Cardiomyopathy (DCM) | Not Yet Recruiting | 2026-03-20 |
| NCT06282432 | Long-Term Follow-Up (LTFU) for Gene Therapy of Leukocyte Adhesion Deficiency-I (LAD-I) | Leukocyte Adhesion Deficiency | Active, Not Recruiting | 2025-12-18 |
Heart Disease (6) · Heart Failure (1)